Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Approves Amgen's Repatha as Add-on Treatment Ages 10 Plus: Bloomberg

09/24/2021 | 03:39pm EDT


ę MT Newswires 2021
All news about AMGEN INC.
09:45aANALYSIS : Capitol Hill drug pricing reform opponents among the biggest beneficiaries of p..
RE
10/21AMGEN : Keeps Quarterly Dividend at $1.76 a Share, Payable Dec. 8 to Stockholders of Recor..
MT
10/21AMGEN : Announces 2021 Fourth Quarter Dividend
PR
10/21Amgen Inc. Declares Dividend for the Fourth Quarter of 2021, Payable on December 8, 202..
CI
10/21AMGEN : Introducing Undruggable, a New Serial Podcast from Amgen R&D Exploring how Multisp..
PU
10/20AMGEN : A Special Edition of Innovation2, brought to you by David and Jim Reese (Brothers2..
PU
10/20CARLYLE : Venture Funds Invest Up to $430 Million in Saama Technologies
MT
10/19AMGEN : Completes Teneobio Acquisition
MT
10/19AMGEN : Successfully Completes Acquisition Of Teneobio, Inc.
PR
10/19AMGEN : Named One of the ‘World's Best Workplaces'
PU
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 010 M - -
Net income 2021 5 801 M - -
Net Debt 2021 22 276 M - -
P/E ratio 2021 20,7x
Yield 2021 3,36%
Capitalization 119 B 119 B -
EV / Sales 2021 5,42x
EV / Sales 2022 5,09x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 209,24 $
Average target price 243,14 $
Spread / Average Target 16,2%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-8.99%118 817
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979